FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Heymach

Research Profile

Disorders

Chemicals & Drugs

Anatomy

Tumor Cell Line

Living Beings

Mouse

Procedures

Physiology

Concepts & Ideas

Treatment Outcome

Co-author Network

Publications

TOP 3
Vikas Bhardwaj; Tina Cascone; Maria Angelica Cortez; Jaden Evans; John V Heymach; Ritsuko U Komaki; Arya Amini; James W Welsh
Modulation of c-Met signaling and cellular sensitivity to radiation: Potential implications for therapy.
James W Welsh; Erik Sulman; Wyatt Unger; Jeffrey S Wefel; Pamela K Allen; Arya Amini; Paul Brown; Joe Y Chang; Su S Chen; Linda L Garland; John V Heymach; Jamie Holt; Edward S Kim; Ritsuko Komaki; Zhongxing Liao; Susan L McGovern; Mark F Munsell; Baldassarre Stea
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Pierre Saintigny; Luisa M Solis Soto; Ignacio I Wistuba; Li Zhang; Young-Ho Ahn; Carmen Behrens; Yulong Chen; Baruch Erez; Sangeeta Goswami; Roy S Herbst; John V Heymach; Waun Ki Hong; Edward S Kim; Jonathan M Kurie; J Jack Lee; Steven Lin; Scott M Lippman; Diane Liu; Erminia Massarelli; Michael S O'Reilly; Yuan Ping; Ja Seok Koo
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Heymach (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Vikas Bhardwaj; Tina Cascone; Maria Angelica Cortez; Jaden Evans; John V Heymach; Ritsuko U Komaki; Arya Amini; James W Welsh
Modulation of c-Met signaling and cellular sensitivity to radiation: Potential implications for therapy.
Cancer 2013;119(10):1768-75.
2013: James W Welsh; Erik Sulman; Wyatt Unger; Jeffrey S Wefel; Pamela K Allen; Arya Amini; Paul Brown; Joe Y Chang; Su S Chen; Linda L Garland; John V Heymach; Jamie Holt; Edward S Kim; Ritsuko Komaki; Zhongxing Liao; Susan L McGovern; Mark F Munsell; Baldassarre Stea
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(7):895-902.
2013: Pierre Saintigny; Luisa M Solis Soto; Ignacio I Wistuba; Li Zhang; Young-Ho Ahn; Carmen Behrens; Yulong Chen; Baruch Erez; Sangeeta Goswami; Roy S Herbst; John V Heymach; Waun Ki Hong; Edward S Kim; Jonathan M Kurie; J Jack Lee; Steven Lin; Scott M Lippman; Diane Liu; Erminia Massarelli; Michael S O'Reilly; Yuan Ping; Ja Seok Koo
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.
Cancer research 2013;73(2):571-82.
2012: Yuji Piao; Amado J Zurita; Verlene Henry; John V Heymach; Lindsay Holmes; Ji Liang; John F de Groot
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Neuro-oncology 2012;14(11):1379-92.
2012: Lauren Averett Byers; Kevin R Coombes; Lixia Diao; Boris Duchemann; You Hong Fan; Junya Fujimoto; Luc Girard; Uma Giri; Bonnie S Glisson; Vikas Bhardwaj; Neda Kalhor; Scott M Lippman; Wenbin Liu; Fatemeh Masrorpour; Gordon B Mills; John D Minna; Monique B Nilsson; Michael Peyton; Pierre Saintigny; Li Shen; Praveen Tumula; Jing Wang; Stephanie Weber; John N Weinstein; James Welsh; Ignacio I Wistuba; John Yordy; John V Heymach
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Cancer discovery 2012;2(9):798-811.
2012: Pierre Saintigny; Banibrata Sen; Ignacio I Wistuba; Li Zhang; Luc Girard; John V Heymach; Scott M Lippman; John D Minna; Shaohua Peng; Faye M Johnson
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
Molecular cancer therapeutics 2012;11(9):2021-32.
2012: Jose Luis Lopez Guerra; Stephen G Swisher; Yan Zhuang; Steven H Lin; James D Cox; Daniel Gomez; John V Heymach; David S Hong; Ritsuko Komaki; Zhongxing Liao
Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis.
International journal of radiation oncology, biology, physics 2012;84(1):e61-7.
2012: Hai T Tran; Amado J Zurita; Rafael G Amado; Katherine L Baker-Neblett; Robert A Figlin; Thomas E Hutson; Ying Lin; Yuan Liu; Anne-Marie Martin; Lini N Pandite; Cora N Sternberg; John V Heymach
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
The lancet oncology 2012;13(8):827-37.
2012: Vikas Bhardwaj; Maria Angelica Cortez; John V Heymach; Ritsuko Komaki; David Molkentine; Anupama Munshi; Uma Raju; Kie Kian Ang; Yanai Zhan; James Welsh
C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(8):1211-7.
2012: Joaquin Mateo; John V Heymach; Amado J Zurita
Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
Molecular diagnosis & therapy 2012;16(3):151-61.
2012: Maria Hernandez-Yanez; John V Heymach; Amado J Zurita
Circulating biomarkers in advanced renal cell carcinoma: clinical applications.
Current oncology reports 2012;14(3):221-9.
2012: Xiaoying Liu; John Minna; Jack A Roth; Stephen G Swisher; Ji Wang; Li Wang; Michael Wang; Shuhong Wu; Luc Girard; Wei Guo; John V Heymach; Edward S Kim; Bingbing Dai; Bingliang Fang
Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells.
Biochemical pharmacology 2012;83(10):1456-64.
2012: Andrea Rabellino; Alessandro Rimessi; Julie Teruya-Feldstein; Shwu-Yuan Wu; Lauren A Byers; Brandon Carter; Cheng-Ming Chiang; Luc Girard; John V Heymach; Georgia Konstantinidou; Pier Paolo Scaglioni
The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.
Cancer research 2012;72(9):2275-84.
2012: Nathan T Ihle; Edward S Kim; Jill E Larsen; J Jack Lee; Scott M Lippman; Suyu Liu; John D Minna; Vassiliki A Papadimitrakopoulou; Mena F Abdelmelek; George R Blumenschein; Lauren A Byers; Lu Chen; Kevin R Coombes; Lixia Diao; Roy S Herbst; John V Heymach; Waun K Hong; Pierre Saintigny; Ximing Tang; Anne Tsao; Jing Wang; Ignacio I Wistuba; Shuxing Zhang; Garth Powis
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Journal of the National Cancer Institute 2012;104(3):228-39.
2012: Tina Cascone; John V Heymach
Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(4):441-4.
2012: Michael A James; John Minna; Yian Wang; Weidong Wen; Lauren A Byers; Kevin R Coombes; Luc Girard; John V Heymach; Ming You
Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.
PloS one 2012;7(6):e36116.
2012: Yong He; John V Heymach; Wayne L Hofstetter; Wenxian Hu; Yiling Lu; Apar Pataer; Jack A Roth; Stephen G Swisher; Jing Wang; Li Wang; Ignacio I Wistuba; Yanbin Zhou; Zhen Zhou; Lauren Averett Byers; Arlene M Correa; Lixia Diao; Chengcheng Guo; Wei Guo; Bingliang Fang
Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters.
PloS one 2012;7(2):e31087.
2011: Anne S Tsao; John V Heymach
Mesothelioma and small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(11 Suppl 4):S1825-6.
2011: Robert L Coleman; Linda R Duska; Michael E Garcia; John V Heymach; Revathy B Iyer; Edward F Jackson; Robert Jaffe; Aparna A Kamat; Vikas Kundra; Debbie L Miller; Susan C Modesitt; Chaan S Ng; Pedro T Ramirez; Kathleen M Schmeler; Anil K Sood
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
The lancet oncology 2011;12(12):1109-17.
2011: Christopher Lieu; Michael Overman; Hai Tran; John V Heymach; Scott Kopetz
Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(19):6130-9.
2011: John V Heymach; Ajaikumar B Kunnumakkara; Thomas J Polascik; Mack T Ruffin; Pierre Saintigny; Terry J Shackleford; Denise Clutter Snyder; Hai T Tran; Robin T Vollmer; Melanie Wergin; Shaoyu Yan; Suk-Young Yoo; Bharat B Aggarwal; Mark Dewhirst; Kim-Anh Do; Wendy Demark-Wahnefried
Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer.
Cancer prevention research (Philadelphia, Pa.) 2011;4(10):1590-8.
2011: Yang Xie; Guanghua Xiao; Carmen Behrens; Kevin R Coombes; Kathy Danenberg; Heidi S Erickson; Luc Girard; John V Heymach; John D Minna; Cesar Moran; Gabriela Raso; Jack Roth; Luisa M Solis; Ignacio I Wistuba
Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(17):5705-14.
2011: Fei Yang; Ximing Tang; Erick Riquelme; Carmen Behrens; Monique B Nilsson; Uma Giri; Marileila Varella-Garcia; Lauren A Byers; Heather Y Lin; Jing Wang; Maria G Raso; Luc Girard; Kevin Coombes; J Jack Lee; Roy S Herbst; John D Minna; John V Heymach; Ignacio I Wistuba
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.
Cancer research 2011;71(16):5512-21.
2011: Floriana Morgillo; Pierre Saintigny; Teresa Troiani; Concetta Tuccillo; E D'Aiuto; Raffaele De Palma; John V Heymach; Erika Martinelli; L Berrino; Tina Cascone; Fortunato Ciardiello
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
British journal of cancer 2011;105(3):382-92.
2011: John F de Groot; Lisa De Angelis; Mark Gilbert; B Nebiyou Bekele; Kevin A Camphausen; Alice Chen; Timothy F Cloughesy; Andrew Lassman; Jun Liu; Minesh Mehta; Yuji Piao; Michael Prados; H Ian Robins; Hai Tran; Patrick Y Wen; Hua-Kang Wu; W K A Yung; John V Heymach
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(14):4872-81.
2011: R S Bhatt; D George; Michael B Atkins; A Norden-Zfoni; A O'Neill; Vikas P Sukhatme; P Y Wen; H K Wu; L Zhang; Amado J Zurita; John V Heymach
Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma.
British journal of cancer 2011;105(1):112-7.
2011: Edward S Kim; J Jack Lee; Scott M Lippman; Suyu Liu; Li Mao; Vassiliki Papadimitrakopoulou; David J Stewart; Ximing Tang; Hai T Tran; Anne Tsao; Ignacio I Wistuba; Christine M Alden; George R Blumenschein; Suzanne E Davis; Jeremy Erasmus; Frank Fossella; Sanjay Gupta; Roy S Herbst; John V Heymach; Marshall E Hicks; Bruce E Johnson; Fadlo R Khuri; Merrill S Kies; Waun K Hong
The BATTLE trial: personalizing therapy for lung cancer.
Cancer discovery 2011;1(1):44-53.
2011: Tina Cascone; Matthew H Herynk; Li Xu; Zhiqiang Du; Humam Kadara; Monique B Nilsson; Carol J Oborn; Yun-Yong Park; Baruch Erez; Jörg J Jacoby; Ju Seog Lee; Heather Y Lin; Fortunato Ciardiello; Roy S Herbst; Robert R Langley; John V Heymach
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.
The Journal of clinical investigation 2011;121(4):1313-28.
2011: Daisuke Sano; Fumihiko Matsumoto; David R Valdecanas; Mei Zhao; David P Molkentine; Yoko Takahashi; Ehab Y Hanna; Vassiliki A Papadimitrakopoulou; John V Heymach; Luka Milas; Jeffrey N Myers
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(7):1815-27.
2011: Benjamin J Moeller; John S Yordy; Michelle D Williams; Uma Giri; Uma Raju; David P Molkentine; Lauren A Byers; John V Heymach; Michael D Story; J Jack Lee; Erich M Sturgis; Randal S Weber; Adam S Garden; K Kian Ang; David L Schwartz
DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(7):2035-43.
2011: Jonathon D Roybal; Yi Zang; Young-Ho Ahn; Yanan Yang; Don L Gibbons; Brandi N Baird; Cristina Alvarez; Nishan Thilaganathan; Diane D Liu; Pierre Saintigny; John V Heymach; Chad J Creighton; Jonathan M Kurie
miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1.
Molecular cancer research : MCR 2011;9(1):25-35.
2010: Meera Nanjundan; Lauren Averett Byers; Mark S Carey; Doris R Siwak; Maria Gabriela Raso; Lixia Diao; Jing Wang; Kevin R Coombes; Jack A Roth; Gordon B Mills; Ignacio I Wistuba; John D Minna; John V Heymach
Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(12):1894-904.
2010: Roy S Herbst; Yan Sun; Wilfried E E Eberhardt; Paul Germonpré; Nagahiro Saijo; Caicun Zhou; Jie Wang; Longyun Li; Fairooz Kabbinavar; Yukito Ichinose; Shukui Qin; Li Zhang; Bonne Biesma; John V Heymach; Peter Langmuir; Sarah J Kennedy; Hiroomi Tada; Bruce E Johnson
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
The lancet oncology 2010;11(7):619-26.
2010: Lauren Averett Byers; F Christopher Holsinger; Merrill S Kies; William N William; Adel K El-Naggar; J Jack Lee; Jianhua Hu; Adriana Lopez; Hai T Tran; Shaoyu Yan; Zhiqiang Du; K Kian Ang; Bonnie S Glisson; Maria Gabriela Raso; Ignacio I Wistuba; Jeffrey N Myers; Waun Ki Hong; Vassiliki A Papadimitrakopoulou; Scott M Lippman; John V Heymach
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.
Molecular cancer therapeutics 2010;9(6):1755-63.
2010: Monique B Nilsson; P E Zage; L Zeng; Lei Xu; T Cascone; H K Wu; Babita Saigal; Patrick A Zweidler-McKay; John V Heymach
Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
Oncogene 2010;29(20):2938-49.
2010: Peter E Zage; Lizhi Zeng; Shana Palla; Wendy Fang; Monique B Nilsson; John V Heymach; Patrick A Zweidler-McKay
A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
Cancer 2010;116(10):2465-75.
2010: Lei Xu; M B Nilsson; P Saintigny; T Cascone; Matthew H Herynk; Z Du; P G Nikolinakos; Ying Yang; Ludmila Prudkin; Diane Liu; J Jack Lee; Faye M Johnson; Kwong-Kwok Wong; L Girard; Adi F Gazdar; John D Minna; Jonathan M Kurie; Ignacio I Wistuba; John V Heymach
Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells.
Oncogene 2010;29(18):2616-27.
2010: Rupal S Bhatt; Jaime Merchan; Robert Parker; Hua-Kang Wu; Liang Zhang; Virginia Seery; John V Heymach; Michael B Atkins; David McDermott; Vikas P Sukhatme
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
Cancer 2010;116(7):1751-6.
2010: Petros G Nikolinakos; Nasser Altorki; David Yankelevitz; Hai T Tran; Shaoyu Yan; Dilip Rajagopalan; Walter Bordogna; Lone H Ottesen; John V Heymach
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
Cancer research 2010;70(6):2171-9.
2010: Scott Kopetz; Paulo M Hoff; Jeffrey S Morris; Robert A Wolff; Cathy Eng; Katrina Y Glover; Rosnie B Adinin; Michael J Overman; Vicente Valero; Sijin Wen; Christopher Lieu; Shaoyu Yan; Hai T Tran; Lee M Ellis; James L Abbruzzese; John V Heymach
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):453-9.
2010: Emer O Hanrahan; Heather Y Lin; Edward S Kim; Shaoyu Yan; Danny Z Du; Kathryn S McKee; Hai T Tran; J Jack Lee; Anderson Ryan; Peter Langmuir; Bruce E Johnson; John V Heymach
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(2):193-201.
2010: Jing Wang; Lauren A Byers; John S Yordy; Wenbin Liu; Li Shen; Keith A Baggerly; Uma Giri; Jeffrey N Myers; K Kian Ang; Michael D Story; Luc Girard; John D Minna; John V Heymach; Kevin R Coombes
Blasted cell line names.
Cancer informatics 2010;9():251-5.
2009: Lauren Averett Byers; Banibrata Sen; Babita Saigal; Lixia Diao; Jing Wang; Meera Nanjundan; Tina Cascone; Gordon B Mills; John V Heymach; Faye M Johnson
Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):6852-61.
2009: William Kim; Samanthi Perera; Bing Zhou; Julian Carretero; Jen Jen Yeh; Samuel A Heathcote; Autumn L Jackson; Petros Nikolinakos; Beatriz Ospina; George Naumov; Kathleyn A Brandstetter; Victor J Weigman; Sara Zaghlul; David Hayes; Robert F Padera; John V Heymach; Andrew L Kung; Norman E Sharpless; William G Kaelin; Kwok-Kin Wong
HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice.
The Journal of clinical investigation 2009;119(8):2160-70.
2009: Emer O Hanrahan; Anderson Ryan; Helen Mann; Sarah J Kennedy; Peter Langmuir; Ronald B Natale; Roy S Herbst; Bruce E Johnson; John V Heymach
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(10):3600-9.
2009: George N Naumov; Monique B Nilsson; Tina Cascone; Alexandra Briggs; Oddbjorn Straume; Lars A Akslen; Eugene Lifshits; Lauren Averett Byers; Li Xu; Hua-Kang Wu; Pasi A Janne; Susumu Kobayashi; Balazs Halmos; Daniel Tenen; Xi M Tang; Jeffrey Engelman; Beow Yeap; Judah Folkman; Bruce E Johnson; John V Heymach
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(10):3484-94.
2009: Amado J Zurita; Eric Jonasch; Hua-Kang Wu; Hai T Tran; John V Heymach
Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma.
Cancer 2009;115(10 Suppl):2346-54.
2009: William N William; John V Heymach; Edward S Kim; Scott M Lippman
Molecular targets for cancer chemoprevention.
Nature reviews. Drug discovery 2009;8(3):213-25.
2009: Keyi Zhu; Waikin Chan; John V Heymach; Miles Wilkinson; David J McConkey
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.
Cancer research 2009;69(5):1836-43.
2009: Patrizia Mancuso; Pierluigi Antoniotti; Jessica Quarna; Angelica Calleri; Cristina Rabascio; Carlo Tacchetti; Paola Braidotti; Hua-Kang Wu; Amado J Zurita; Luca Saronni; John B Cheng; David R Shalinsky; John V Heymach; Francesco Bertolini
Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):267-73.
2008: John V Heymach; Luis Paz-Ares; Filippo de Braud; Martin Sebastian; David J Stewart; Wilfried E E Eberhardt; Anantbhushan A Ranade; Graham Cohen; Jose Manuel Trigo; Alan B Sandler; Philip D Bonomi; Roy S Herbst; Annetta D Krebs; James Vasselli; Bruce E Johnson
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(33):5407-15.
2008: Roy S Herbst; John V Heymach; Scott M Lippman
Lung cancer.
The New England journal of medicine 2008;359(13):1367-80.
2008: Tina Cascone; Maria Pia Morelli; Floriana Morgillo; Woo-Young Kim; Gabriella Rodolico; Stefano Pepe; Giampaolo Tortora; Liberato Berrino; Ho-Young Lee; John V Heymach; Fortunato Ciardiello
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Journal of cellular physiology 2008;216(3):698-707.
2008: Sendia Kim; Sang Lee; Arin K Greene; Danielle A Arsenault; Hau Le; Jonathan Meisel; Katherine Novak; Evelyn Flynn; John V Heymach; Mark Puder
Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib.
The Journal of surgical research 2008;149(1):115-9.
2008: Petros Nikolinakos; John V Heymach
The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(6 Suppl 2):S131-4.
2008: Thomas J Lynch; George R Blumenschein; Jeffrey A Engelman; Igor Espinoza-Delgado; Ramaswamy Govindan; Jeff Hanke; Nasser H Hanna; John V Heymach; Fred R Hirsch; Pasi A Janne; Rogerio Lilenbaum; Ronald B Natale; Gregory J Riely; Lecia V Sequist; Geoffrey I Shapiro; Alice Shaw; Frances A Shepherd; Mark A Socinski; A Gregory Sorensen; Heather A Wakelee; Aaron Weitzman
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(6 Suppl 2):S107-12.
2008: Wenhong Ren; Borys Korchin; Quan-Sheng Zhu; Caimiao Wei; Adam Dicker; John V Heymach; Alexander Lazar; Raphael E Pollock; Dina lev
Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(9):2785-95.
2008: Dhara N Amin; Diane R Bielenberg; Eugene Lifshits; John V Heymach; Michael Klagsbrun
Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
Microvascular research 2008;76(1):15-22.
2008: Cesare Gridelli; Andrea Ardizzoni; Fortunato Ciardiello; Nasser Hanna; John V Heymach; Francesco Perrone; Rafael Rosell; Frances A Shepherd; Nick Thatcher; Johan Vansteenkiste; Luigi De Petris; Massimo Di Maio; Filippo De Marinis
Second-line treatment of advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(4):430-40.
2007: Jeffrey A Engelman; Kreshnik Zejnullahu; Christopher-Michael Gale; Eugene Lifshits; Andrea J Gonzales; Takeshi Shimamura; Feng Zhao; Patrick W Vincent; George N Naumov; James E Bradner; Irene W Althaus; Leena Gandhi; Geoffrey I Shapiro; James M Nelson; John V Heymach; Matthew Meyerson; Kwok-Kin Wong; Pasi A Janne
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
Cancer research 2007;67(24):11924-32.
2007: Ashraful Hoque; Howard L Parnes; Michael E Stefanek; John V Heymach; Powel H Brown; Scott M Lippman
Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research.
Cancer research 2007;67(19):8989-93.
2007: John V Heymach; Bruce E Johnson; Diane Prager; Edit Csada; Jaromír Roubec; Milos Pesek; Irena Spásová; Chandra P Belani; István Bodrogi; Shirish M Gadgeel; Sarah J Kennedy; Jeannie Hou; Roy S Herbst
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(27):4270-7.
2007: Emer O Hanrahan; John V Heymach
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4617-22.
2007: Thomas J Lynch; Philip D Bonomi; Charles Butts; Angela M Davies; Jeffrey A Engelman; Ramaswamy Govindan; Roy S Herbst; John V Heymach; Bruce E Johnson; Renato G Martins; Roman Perez-Soler; Gregory J Riely; Alan B Sandler; Lecia V Sequist; Mark A Socinski; Kwok-Kin Wong; Carol S Hart
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4583-8.
2007: Scott M Lippman; John V Heymach
The convergent development of molecular-targeted drugs for cancer treatment and prevention.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4035-41.
2007: Paul Beaudry; Yasuhiro Hida; Taturo Udagawa; Ian P J Alwayn; Arin K Greene; Danielle A Arsenault; Judah Folkman; John V Heymach; Sandra W Ryeom; Mark Puder
Endothelial progenitor cells contribute to accelerated liver regeneration.
Journal of pediatric surgery 2007;42(7):1190-8.
2007: Anat Norden-Zfoni; Jayesh Desai; Judith Manola; Paul Beaudry; Jeremy Force; ROBERT G MAKI; Judah Folkman; Carlo L Bello; Charles Baum; Sam E DePrimo; David R Shalinsky; George D Demetri; John V Heymach
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2643-50.
2007: Maromi K Sakurai; Sang Lee; Danielle A Arsenault; Vania Nose; Jay M Wilson; John V Heymach; Mark Puder
Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy.
American journal of physiology. Lung cellular and molecular physiology 2007;292(3):L742-7.
2007: Lauren A Byers; John V Heymach
Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer.
Clinical lung cancer 2007;8 Suppl 2():S79-85.
2007: Roy S Herbst; John V Heymach; Michael S O'Reilly; Amir Onn; Anderson Ryan
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.
Expert opinion on investigational drugs 2007;16(2):239-49.
2007: Aparna A Kamat; Tae Jin Kim; Charles N Landen; Chunhua Lu; Liz Y Han; Yvonne G Lin; William M Merritt; Premal H Thaker; David M Gershenson; Farideh Z Bischoff; John V Heymach; Robert B Jaffe; Robert L Coleman; Anil K Sood
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Cancer research 2007;67(1):281-8.
2006: Monique Nilsson; John V Heymach
Vascular endothelial growth factor (VEGF) pathway.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(8):768-70.
2006: Jeffrey A Engelman; Toru Mukohara; Kreshnik Zejnullahu; Eugene Lifshits; Ana M Borrás; Christopher-Michael Gale; George N Naumov; Beow Y Yeap; Emily Jarrell; Jason Sun; Sean Tracy; Xiaojun Zhao; John V Heymach; Bruce E Johnson; Lewis C Cantley; Pasi A Janne
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
The Journal of clinical investigation 2006;116(10):2695-706.
2006: George R Blumenschein; John V Heymach
Angiogenesis inhibitors for lung cancer: clinical developments and future directions.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(7):744-8.
2006: Matthew H Kulke; Emily K Bergsland; David P Ryan; Peter C Enzinger; Thomas J Lynch; Andrew X Zhu; Jeffrey A Meyerhardt; John V Heymach; William E Fogler; Carolyn Sidor; Ann Michelini; Kate Kinsella; Alan P Venook; Charlie S Fuchs
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3555-61.
2006: John V Heymach; Monique Nilsson; George R Blumenschein; Vassiliki A Papadimitrakopoulou; Roy Herbst
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 2):4441s-4445s.
2006: Thomas J Lynch; Alex A. Adjei; Paul A Bunn; Tim G Eisen; Jeffrey A Engelman; Glenwood Goss; Daniel A Haber; John V Heymach; Pasi A Janne; Bruce E Johnson; David H Johnson; Rogerio Lilenbaum; Matthew Meyerson; Alan B Sandler; Lecia V Sequist; Jeffrey Settleman; Kwok-Kin Wong; Carol S Hart
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 2):4365s-4371s.
2006: David Lee; John V Heymach
Emerging antiangiogenic agents in lung cancer.
Clinical lung cancer 2006;7(5):304-8.
2005: Ilhan Celik; Oguzkan Sürücü; Carsten Dietz; John V Heymach; Jeremy Force; Iris Höschele; Christian M Becker; Judah Folkman; Oliver Kisker
Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve.
Cancer research 2005;65(23):11044-50.
2005: John V Heymach
ZD6474--clinical experience to date.
British journal of cancer 2005;92 Suppl 1():S14-20.
2005: Paul Beaudry; Jeremy Force; George N Naumov; Andrew Wang; Cheryl H Baker; Anderson Ryan; Shay Soker; Bruce E Johnson; Judah Folkman; John V Heymach
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3514-22.
2005: Darren W Davis; Ryan Takamori; Chandrajit P Raut; Henry Q Xiong; Roy S Herbst; Walter M Stadler; John V Heymach; George D Demetri; Asif Rashid; Yu Shen; Sijin Wen; James L Abbruzzese; David J McConkey
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):678-89.
2004: John V Heymach; Jayesh Desai; Judith Manola; Darren W Davis; David J McConkey; David Harmon; David P Ryan; Glenwood Goss; Travis Quigley; Annick D Van den Abbeele; Stuart G Silverman; Susan Connors; Judah Folkman; Christopher D M Fletcher; George D Demetri
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5732-40.
2004: John V Heymach; D H Johnson; Fadlo R Khuri; H Safran; LL Schlabach; F Yunus; Russell F DeVore; P M De Porre; H M Richards; X Jia; S Zhang; Bruce E Johnson
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(8):1187-93.
2004: Bruce E Johnson; John V Heymach
Farnesyl transferase inhibitors for patients with lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4254s-4257s.
2003: Gunter Schuch; John V Heymach; Masashi Nomi; Marcelle Machluf; Jeremy Force; Anthony Atala; Joseph P Eder; Judah Folkman; Shay Soker
Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells.
Cancer research 2003;63(23):8345-50.
2001: John V Heymach
Angiogenesis and antiangiogenic approaches to sarcomas.
Current opinion in oncology 2001;13(4):261-9.